156 related articles for article (PubMed ID: 31372987)
21. [Primary cutaneous peripheral T-cell lymphoma (not otherwise specified)].
Mühlhoff C; Gassler N; Megahed M
Hautarzt; 2011 May; 62(5):332-5. PubMed ID: 21437704
[TBL] [Abstract][Full Text] [Related]
22. Childhood cutaneous natural killer/T lymphoma successfully treated with only one course of chemotherapy and incomplete tumor resection.
Miyazaki M; Lin YW; Okada M; Hamahata K; Kubota M
Haematologica; 2001 Aug; 86(8):883-4. PubMed ID: 11524256
[No Abstract] [Full Text] [Related]
23. Primary Cutaneous T-cell Lymphoma with Aberrant Expression of CD20.
Frings VG; Roth S; Riedmiller AL; Schäfer K; Goebeler M; Rosenwald A; Geissinger E; Wobser M
Acta Derm Venereol; 2017 Apr; 97(4):534-536. PubMed ID: 27840885
[No Abstract] [Full Text] [Related]
24. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Rook AH; Gelfand JM; Wysocka M; Troxel AB; Benoit B; Surber C; Elenitsas R; Buchanan MA; Leahy DS; Watanabe R; Kirsch IR; Kim EJ; Clark RA
Blood; 2015 Sep; 126(12):1452-61. PubMed ID: 26228486
[TBL] [Abstract][Full Text] [Related]
25. Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M; Gniadecki R
Dermatol Clin; 2008 Jan; 26 Suppl 1():45-7. PubMed ID: 18405187
[No Abstract] [Full Text] [Related]
26. Lymphomatoid papulosis and Ki-1 (CD30)-positive cutaneous large cell lymphomas.
Kaudewitz P; Burg G
Semin Diagn Pathol; 1991 May; 8(2):117-24. PubMed ID: 1651550
[No Abstract] [Full Text] [Related]
27. Cutaneous NK/T-cell lymphoma preceded by persistent facial angioedema.
Yun GJ; Kim KM; Bae YJ; Cho YS; Moon HB; Lee J; Kim TB
Acta Derm Venereol; 2010 May; 90(3):328-9. PubMed ID: 20526568
[No Abstract] [Full Text] [Related]
28. Cutaneous natural killer (NK) / T-cell lymphoma: nasal type with extensive facial destruction.
Kost Al M; Kost Alová M; Belada D; Laco J
Int J Dermatol; 2009 Dec; 48(12):1338-42. PubMed ID: 19930492
[No Abstract] [Full Text] [Related]
29. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC).
Petrella T; Dalac S; Maynadié M; Mugneret F; Thomine E; Courville P; Joly P; Lenormand B; Arnould L; Wechsler J; Bagot M; Rieux C; Bosq J; Avril MF; Bernheim A; Molina T; Devidas A; Delfau-Larue MH; Gaulard P; Lambert D
Am J Surg Pathol; 1999 Feb; 23(2):137-46. PubMed ID: 9989839
[TBL] [Abstract][Full Text] [Related]
30. Intralesional cisplatin for the treatment of cutaneous B-cell lymphoma.
Kempf W; Dummer R; Schmid MH; Fritz T; Wüthrich B; Burg G
Arch Dermatol; 1998 Nov; 134(11):1343-5. PubMed ID: 9828865
[No Abstract] [Full Text] [Related]
31. TCRVb repertoire abnormalities in patients with cutaneous T-cell lymphoma.
Papadavid E; Kapsimali V; Psarra A; Antoniou C; Papasteriadi C; Ekonomidou J; Anagnostou D; Nikolaou V; Kounaki D; Dalamaga M; Bamia C; Stratigos A; Stavrianeas N; Katsambas A
Leuk Lymphoma; 2009 Jan; 50(1):130-2. PubMed ID: 19152167
[No Abstract] [Full Text] [Related]
32. 13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma.
Chow JM; Cheng AL; Su IJ; Wang CH
Cancer; 1991 May; 67(10):2490-4. PubMed ID: 1849787
[TBL] [Abstract][Full Text] [Related]
33. [Cutaneous T-cell lymphoma].
Dippel E; Gellrich S; Klemke CD; Goerdt S; Sterry W
J Dtsch Dermatol Ges; 2003 Dec; 1(12):965-80; quiz 981-2. PubMed ID: 16285650
[No Abstract] [Full Text] [Related]
34. Management of cutaneous T-cell lymphoma.
Duhovic C; Child F; Wain EM
Clin Med (Lond); 2012 Apr; 12(2):160-4. PubMed ID: 22586794
[No Abstract] [Full Text] [Related]
35. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop.
Santucci M; Pimpinelli N; Massi D; Kadin ME; Meijer CJ; Müller-Hermelink HK; Paulli M; Wechsler J; Willemze R; Audring H; Bernengo MG; Cerroni L; Chimenti S; Chott A; Díaz-Pérez JL; Dippel E; Duncan LM; Feller AC; Geerts ML; Hallermann C; Kempf W; Russell-Jones R; Sander C; Berti E;
Cancer; 2003 Feb; 97(3):610-27. PubMed ID: 12548603
[TBL] [Abstract][Full Text] [Related]
36. Blastic natural killer cell and extranodal natural killer cell-like T-cell lymphoma presenting in the skin: report of six cases from the UK.
Child FJ; Mitchell TJ; Whittaker SJ; Calonje E; Spittle M; Crocker J; Russell-Jones R
Br J Dermatol; 2003 Mar; 148(3):507-15. PubMed ID: 12653743
[TBL] [Abstract][Full Text] [Related]
37. [Cutaneous cytotoxic T-cell lymphoma].
Weinstabl A; Megahed M; Rütten A; Rübben A
Hautarzt; 2011 May; 62(5):329-32. PubMed ID: 21445701
[TBL] [Abstract][Full Text] [Related]
38. Primary cutaneous T cell lymphomas: photochemotherapy immunomodulation with analysis of the inflammatory-expansive cellular dynamic.
Werber-Bandeira L; Herdy AM; Pagani EA; Filgueira AL
Dermatol Ther; 2014; 27(2):74-8. PubMed ID: 24703262
[TBL] [Abstract][Full Text] [Related]
39. The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Rook AH; Zaki MH; Wysocka M; Wood GS; Duvic M; Showe LC; Foss F; Shapiro M; Kuzel TM; Olsen EA; Vonderheid EC; Laliberte R; Sherman ML
Ann N Y Acad Sci; 2001 Sep; 941():177-84. PubMed ID: 11594571
[TBL] [Abstract][Full Text] [Related]
40. Topical imiquimod therapy for cutaneous T-cell lymphoma.
Do JH; McLaughlin SS; Gaspari AA
Skinmed; 2003; 2(5):316-8. PubMed ID: 14673267
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
